
Xenon Pharmaceuticals (XENE) Stock Forecast & Price Target
Xenon Pharmaceuticals (XENE) Analyst Ratings
Bulls say
Xenon Pharmaceuticals is viewed favorably because azetukalner has the strongest efficacy dataset yet in focal seizures, with −53.2% median seizure reduction versus −10.4% on placebo and RR50 of 54.8% versus 20.8% in a heavily refractory population averaging at least 5 prior failed medications. The company’s epilepsy franchise is further de-risked by more than 1,500 patient years of safety and exposure data, a filed NDA, and a practical profile of day-one therapeutic dosing, no titration, and no DRESS risk, which could support broad adoption and meaningful commercial penetration. While the psychiatry program is paused pending safety clarity, its pain assets add longer-dated optionality, and the wholly owned Nav1.7 and Kv7 programs provide additional mechanistic breadth in a large unmet-need market.
Bears say
Xenon Pharmaceuticals is facing a weakened fundamental outlook because its psychiatric program was paused after a DSMB review identified neuropsychiatric adverse events, forcing management to remove the MDD opportunity from valuation and increasing uncertainty around the therapeutic window. The setback is compounded by X-NOVA2 closing at about 360 patients versus a 450 target, with topline now expected in 1Q27, while the company still must prove that dosing changes can preserve efficacy without worsening safety. Although epilepsy remains the core value driver and the NDA has been submitted, the stock carries added near-term risk from regulatory delay, competitive pressure, commercial-execution uncertainty, and financing needs until cash flow turns positive.
This aggregate rating is based on analysts' research of Xenon Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Xenon Pharmaceuticals (XENE) Analyst Forecast & Price Prediction
Start investing in Xenon Pharmaceuticals (XENE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Xenon Pharmaceuticals (XENE) Forecast
Xenon Pharmaceuticals (XENE) Analyst Forecast & Price Prediction
Start investing in Xenon Pharmaceuticals (XENE)
Order type
Buy in
Order amount
Est. shares
0 shares